Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07402382 · ClinicalTrials.gov registry record · NA
Effects of an Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose Control in Peri/Post-Menopausal Women
A NA study of Post-menopause and Glucose Monitoring, Continuous, sponsored by Nutrition 21.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07402382 is a NA study of Post-menopause and Glucose Monitoring, Continuous that is actively recruiting participants, run by Nutrition 21. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07402382, a NA study of Post-menopause and Glucose Monitoring, Continuous, is actively recruiting participants, sponsored by Nutrition 21.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic control over a 24-hour period. The main questions the study aims to answer are: * Does the use of an amylopectin chromium blend in peri- and post-menopausal women help to support positive protein balance * Can the affect be achieved using a concentrated dose Researchers will compare the nutritional supplement to a placebo (amylopectin alone) to see if the amylopectin chromium blend can promote positive protein balance. A concentrated dose of the supplement will also be evaluated for comparative effectiveness. Participants will: * Consume the nutritional supplement (standard or concentrated dose) or placebo acutely after a short resistance exercise bout * Complete four in-person visits, including the single-day intervention Results from this research may help guide future nutritional strategies to support healthy aging, muscle function, and overall metabolic health.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Amylopectin-chromium blend
Study Locations (1)
Ohio
- The Center for Applied Health Sciences - Canfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07402382
The ClinicalTrials.gov registry entry for NCT07402382 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nutrition 21, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Post-menopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07402382 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07402382 about?
NCT07402382 is a clinical study titled "Effects of an Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose Control in Peri/Post-Menopausal Women". The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic ...
What is the current status of trial NCT07402382?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-11-01. Estimated completion is 2026-09-30.
What conditions does trial NCT07402382 study?
This clinical trial studies the following conditions: Post-menopause, Glucose Monitoring, Continuous, Whole Body Protein Metabolism, Peri-menopausal Women.
What interventions are being tested in trial NCT07402382?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Amylopectin-chromium blend (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07402382?
This trial is sponsored by Nutrition 21, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07402382 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.